Pharma major Novartis is becoming more optimistic about some of its biggest growth drugs, even as investors question the company's ability to sustain growth beyond 2031 and offset the financial impact of older drugs' patent expiries.
The Swiss drugmaker now expects multiple sclerosis drug Kesimpta, leukaemia treatment Scemblix, and cholesterol medicine Leqvio to generate $18 billion in peak sales, up from a previous forecast of $14 billion combined.
CEO Vas Narasimhan said the upgrades were driven primarily by strong commercial performance, pointing to growing market share for Kesimpta and Scemblix and robust demand for Leqvio in the U.S. and Asia.
Vas Narasimhan, chief executive officer of Novartis AG, during an announcement in the Roosevelt Room of the White House in Washington, DC, US, on Friday, Dec. 19, 2025.
Will Oliver | Bloomberg | Getty Images
"It's really that in-market commercial performance that's driving these upgrades," Narasimhan told reporters on Thursday.
Shares fell 2.4% in mid-morning trading in Switzerland. For investors, the question will be whether those drugs can grow fast enough to offset lost sales as other drugs face competition from cheaper rivals entering the market.
Novartis shares year-to-date.
Even so, the overall growth outlook looked slightly more cautious despite stronger expectations for some key growth drugs.
Novartis projected annual sales growth of 5% through 2031, slightly less ambitious than its previous guidance of between 5% and 6% through 2030, although it covers a different five-year period.
CEO Vas Narasimhan said the revised outlook reflected the expected entry of U.S. generic competition for Kisqali, a breast cancer treatment, in the second half of 2031.
Citi analysts noted the 2031 sales guidance was about 3% above consensus, adding they expect the market to remain skeptical of post-2031 growth, pending further pipeline data.
Novartis has faced several recent clinical setbacks. In September, its closely watched cardiovascular pelacarsen trial failed to show improved cardiovascular outcomes. The following day, its del-desiran drug for muscle-wasting disorder failed in a late-stage trial, sending shares down nearly 11% in its worst single-day drop since 1987.
Narasimhan defended the drugmaker's capital allocation strategy after the failure of its experimental drug del-desiran, which it acquired via a $12 billion deal for Avidity Biosciences earlier this year.
Shareholders have differing views on acquisitions, with some favouring more aggressive dealmaking and others preferring a different approach, Narasimhan said. However, he said Novartis remained confident in its strategy, pointing to a 275% total shareholder return over the past decade, which he said placed the company among the sector's top performers.
Tune in at 11 a.m. ET as Novartis CEO Vas Narasimhan joins CNBC TV. Watch in real time on CNBC+ or the CNBC Pro stream.
Source: CNBC · Elsa Ohlen
At a glance
- Topic
- Business
- Country
- 🇺🇸 US
- Publisher language
- EN
- Added to Allnira